These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 6968281)

  • 41. [Lupus nephropathy with mesangial expansion. Possible association with the anti Sm antibody (author's transl)].
    Reyes PA; Salinas-Madrigal L
    Rev Invest Clin; 1980; 32(2):199-204. PubMed ID: 6968446
    [No Abstract]   [Full Text] [Related]  

  • 42. [Immunofluorescence on Crithidia luciliae in the detection of anti-native DNA antibodies (author's transl)].
    André C; Villeminot S; Bourhala S
    Nouv Presse Med; 1982 Apr; 11(15):1127-30. PubMed ID: 7043393
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Plasmapheresis in the management of systemic lupus erythematosus].
    Wätzig V; Thiel W; Schreiber G
    Dermatol Monatsschr; 1979 Apr; 165(4):305-7. PubMed ID: 456715
    [No Abstract]   [Full Text] [Related]  

  • 44. [Role of plasmapheresis in the treatment of systemic lupus erythematosus].
    Leibowitz G; Ben-Yehuda A; Naparstek Y
    Harefuah; 1990 Mar; 118(6):329-33. PubMed ID: 2189809
    [No Abstract]   [Full Text] [Related]  

  • 45. Anti-DNA activity in Raji cell eluates of sera from patients with systemic lupus erythematosus.
    Tomii M
    Ryumachi; 1981; 21 Suppl():123-7. PubMed ID: 6979800
    [No Abstract]   [Full Text] [Related]  

  • 46. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.
    Leandro MJ; Cambridge G; Edwards JC; Ehrenstein MR; Isenberg DA
    Rheumatology (Oxford); 2005 Dec; 44(12):1542-5. PubMed ID: 16188950
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Plasma exchange therapy in systemic lupus erythematosus (author's transl)].
    Amemiya H
    Nihon Jinzo Gakkai Shi; 1982 Feb; 24(2):205-18. PubMed ID: 7098142
    [No Abstract]   [Full Text] [Related]  

  • 48. [Occupational systemic lupus due to cosmetics (author's transl)].
    Camus JP; Prier A
    Ann Med Interne (Paris); 1980; 131(5):279-80. PubMed ID: 6969565
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Increased levels of serum protein oxidation and correlation with disease activity in systemic lupus erythematosus.
    Morgan PE; Sturgess AD; Davies MJ
    Arthritis Rheum; 2005 Jul; 52(7):2069-79. PubMed ID: 15986354
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antibodies against the VRT101 laminin epitope correlate with human SLE disease activity and can be removed by extracorporeal immunoadsorption.
    Amital H; Heilweil-Harel M; Ulmansky R; Harlev M; Toubi E; Hershko A; Naparstek Y
    Rheumatology (Oxford); 2007 Sep; 46(9):1433-7. PubMed ID: 17686790
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Detection of DNA anti-DNA immune complexes in systemic lupus erythematosus sera (author's transl)].
    Sarai T; Sakamoto K; Miyawaki S; Ofuji T
    Ryumachi; 1982 Feb; 22(1):20-7. PubMed ID: 7089743
    [No Abstract]   [Full Text] [Related]  

  • 52. Antibodies to dsDNA in drug induced lupus erythematosus.
    Cohen MG
    J Rheumatol; 1994 Mar; 21(3):578-9. PubMed ID: 8006909
    [No Abstract]   [Full Text] [Related]  

  • 53. [Initial experience in the treatment of systemic lupus erythematosus using plasmapheresis].
    Simcíková B; Opat P; Rysánek K; Bucek J; Lokaj J; Podrouzková D; Mayer P
    Cas Lek Cesk; 1985 Aug; 124(35):1097-101. PubMed ID: 4028096
    [No Abstract]   [Full Text] [Related]  

  • 54. Effect of steroid administration and plasmapheresis to prevent fetal congenital heart block in patients with systemic lupus erythematosus and/or Sjögren's syndrome.
    Makino S; Yonemoto H; Itoh S; Takeda S
    Acta Obstet Gynecol Scand; 2007; 86(9):1145-6. PubMed ID: 17712660
    [No Abstract]   [Full Text] [Related]  

  • 55. Systemic lupus erythematosus XII: Cytotoxic therapy and pheresis.
    Stevens MB
    Md State Med J; 1984 Jul; 33(7):538-40. PubMed ID: 6381919
    [No Abstract]   [Full Text] [Related]  

  • 56. Systemic lupus erythematosus. Differences between patients who do, and who do not, fulfill classification criteria at the time of diagnosis.
    Lom-Orta H; Alarcon-Segovia D; Diaz-Jouanen E
    J Rheumatol; 1980; 7(6):831-7. PubMed ID: 6970814
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Plasmapheresis in active systemic lupus erythematosus: effects on clinical, serum, and cellular abnormalities. Case report.
    Abdou NI; Lindsley HB; Pollock A; Stechschulte DJ; Wood G
    Clin Immunol Immunopathol; 1981 Apr; 19(1):44-54. PubMed ID: 6452239
    [No Abstract]   [Full Text] [Related]  

  • 58. The use of plasmapheresis in a patient with systemic lupus erythematosus and necrotizing cutaneous ulcers.
    Fruchter L; Gauthier B; Marino F
    J Rheumatol; 1983 Apr; 10(2):341-3. PubMed ID: 6864694
    [No Abstract]   [Full Text] [Related]  

  • 59. [Treatment of systemic lupus erythematosus (I)].
    Font J; Cardellach F; Ingelmo M
    Med Clin (Barc); 1986 Apr; 86(14):604-9. PubMed ID: 3724270
    [No Abstract]   [Full Text] [Related]  

  • 60. Apheresis is of value in SLE.
    Hebert LA
    Trans Am Soc Artif Intern Organs; 1984; 30():697. PubMed ID: 6533962
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.